JP2018090566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018090566A5 JP2018090566A5 JP2017219019A JP2017219019A JP2018090566A5 JP 2018090566 A5 JP2018090566 A5 JP 2018090566A5 JP 2017219019 A JP2017219019 A JP 2017219019A JP 2017219019 A JP2017219019 A JP 2017219019A JP 2018090566 A5 JP2018090566 A5 JP 2018090566A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- lung cancer
- small cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 11
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- -1 6-((3-methoxy-1-methyl-1H-pyrazole-4-yl) amino) -9-methyl-9H-purin-2-yl Chemical group 0.000 claims 5
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 5
- 229960004390 palbociclib Drugs 0.000 claims 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000011885 synergistic combination Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423146P | 2016-11-16 | 2016-11-16 | |
| US62/423146 | 2016-11-16 | ||
| US201762571114P | 2017-10-11 | 2017-10-11 | |
| US62/571114 | 2017-10-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018090566A JP2018090566A (ja) | 2018-06-14 |
| JP2018090566A5 true JP2018090566A5 (cg-RX-API-DMAC7.html) | 2020-12-24 |
Family
ID=60543611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017219019A Pending JP2018090566A (ja) | 2016-11-16 | 2017-11-14 | 非小細胞肺癌の治療のためのｅｇｆｒ ｔ７９０ｍ阻害剤およびｃｄｋ阻害剤の組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190275049A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3541389A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018090566A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043681A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201822769A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018091999A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117530948A (zh) | 2016-12-05 | 2024-02-09 | G1治疗公司 | 化疗方案期间免疫反应的保持 |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| MY205589A (en) | 2018-01-08 | 2024-10-28 | G1 Therapeutics Inc | G1t38 superior dosage regimes |
| KR20200132902A (ko) * | 2018-03-13 | 2020-11-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Egfr 활성화 돌연변이를 갖는 암의 치료 방법 |
| WO2020232292A1 (en) * | 2019-05-15 | 2020-11-19 | Board Of Regents, The University Of Texas System | Methods and compositions for treating non-small cell lung cancer |
| CN114430681A (zh) * | 2019-09-23 | 2022-05-03 | 贝达医药公司 | 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 |
| ES3048697T3 (en) * | 2019-09-30 | 2025-12-11 | Univ Mainz | Cdk4/6 inhibitors for the treatment of psoriasis |
| CN111557943A (zh) * | 2020-04-30 | 2020-08-21 | 天津医科大学总医院 | Pd0332991联合奥希替尼在制备治疗nsclc药物中的应用 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022253222A1 (zh) * | 2021-06-04 | 2022-12-08 | 洪明奇 | 医药组合物治疗肺癌的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060111716A (ko) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
| RU2317296C2 (ru) | 2003-07-11 | 2008-02-20 | Уорнер-Ламберт Компани Ллс | Изетионатная соль селективного ингибитора cdk4 |
| CA2662768A1 (en) | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| EP2958916B1 (en) | 2013-02-21 | 2018-09-12 | Pfizer Inc | Solid forms of a selective cdk4/6 inhibitor |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2016015597A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| AR104068A1 (es) * | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
-
2017
- 2017-11-07 CA CA3043681A patent/CA3043681A1/en not_active Abandoned
- 2017-11-07 US US16/349,941 patent/US20190275049A1/en not_active Abandoned
- 2017-11-07 WO PCT/IB2017/056952 patent/WO2018091999A1/en not_active Ceased
- 2017-11-07 EP EP17808168.3A patent/EP3541389A1/en not_active Withdrawn
- 2017-11-14 JP JP2017219019A patent/JP2018090566A/ja active Pending
- 2017-11-15 TW TW106139406A patent/TW201822769A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018090566A5 (cg-RX-API-DMAC7.html) | ||
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| JP2019503365A5 (cg-RX-API-DMAC7.html) | ||
| MX2021002322A (es) | Nuevos metodos. | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| BRPI0916356A2 (cg-RX-API-DMAC7.html) | ||
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2017530983A5 (cg-RX-API-DMAC7.html) | ||
| JP2012193216A5 (cg-RX-API-DMAC7.html) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2021014029A (es) | Formulaciones, fabricación y usos de imatinib. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2020107416A (ru) | Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| PH12021553056A1 (en) | Modified release formulations and uses thereof | |
| MX2024013020A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CR20240514A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| JP2016505050A5 (cg-RX-API-DMAC7.html) | ||
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| JP2019529569A5 (cg-RX-API-DMAC7.html) | ||
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose |